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ABSTRACT
Esophageal squamous cell carcinoma (ESCC) in humans is a deadly disease 
associated with dietary zinc (Zn)-deficiency. In the rat esophagus, Zn-deficiency 
induces cell proliferation, alters mRNA and microRNA gene expression, and promotes 
ESCC. We investigated whether Zn-deficiency alters cell metabolism by evaluating 
metabolomic profiles of esophageal epithelia from Zn-deficient and replenished 
rats vs sufficient rats, using untargeted gas chromatography time-of-flight mass 
spectrometry (n = 8/group). The Zn-deficient proliferative esophagus exhibits a 
distinct metabolic profile with glucose down 153-fold and lactic acid up 1.7-fold (P 
< 0.0001), indicating aerobic glycolysis (the “Warburg effect”), a hallmark of cancer 
cells. Zn-replenishment rapidly increases glucose content, restores deregulated 
metabolites to control levels, and reverses the hyperplastic phenotype. Integration 
of metabolomics and our reported transcriptomic data for this tissue unveils a link 
between glucose down-regulation and overexpression of HK2, an enzyme that 
catalyzes the first step of glycolysis and is overexpressed in cancer cells. Searching 
our published microRNA profile, we find that the tumor-suppressor miR-143, a 
negative regulator of HK2, is down-regulated in Zn-deficient esophagus. Using in 
situ hybridization and immunohistochemical analysis, the inverse correlation between 
miR-143 down-regulation and HK2 overexpression is documented in hyperplastic Zn-
deficient esophagus, archived ESCC-bearing Zn-deficient esophagus, and human ESCC 
tissues. Thus, to sustain uncontrolled cell proliferation, Zn-deficiency reprograms 
glucose metabolism by modulating expression of miR-143 and its target HK2. Our work 
provides new insight into critical roles of Zn in ESCC development and prevention.
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INTRODUCTION
Although cancer mortality rates have declined 
worldwide since the mid 1980s, esophageal squamous cell 
carcinoma (ESCC), the predominant esophageal cancer 
subtype, has a 5-year survival of only 10% [1]. Due to 
lack of early symptoms, ESCC is typically diagnosed 
at an advanced stage that defies treatment by surgery 
combined with radio/chemotherapy. Thus, clarification of 
the mechanisms underlying the pathogenesis of ESCC and 
development of new prevention and therapeutic strategies 
are critically needed. 
Zinc (Zn)-deficiency (ZD) is recognized as a major 
worldwide public health problem [2-6], affecting ~31% 
of the global population with higher rates in developing 
countries [5]. Although severe ZD is uncommon, mild-
to-moderate ZD is prevalent throughout the world [7]. 
Epidemiologic and clinical studies have implicated dietary 
ZD in the etiology of ESCC [8-10]. Specifically, Abnet 
et al. [11] demonstrated that tissue Zn concentration 
is inversely associated with the subsequent risk of 
developing ESCC. Because Zn is required for the activity 
of hundreds of enzymes, for proper immune function, 
and for the conformation of > 2000 transcription factors 
that control cell proliferation, apoptosis, and signaling 
pathways [12, 13], ZD predisposes to disease by adversely 
affecting many processes.
Cell proliferation is a hall mark of cancer [14]. 
Previously, we showed that rats on a ZD diet for ~6 
weeks develop a hyperplastic esophagus with sustained, 
uncontrolled cell proliferation [15]. In transcriptome 
analyses using DNA microarrays, the ZD esophagus 
showed a distinct gene expression signature with the 
proinflammation mediators S100a8/a9 as the top up-
regulated genes [16]. Zn-replenishment (ZR) rapidly 
restored to control levels the expression of S100A8/A9 
and other genes and reversed the hyperplastic phenotype 
[16]. In addition, prolonged ZD (21 weeks) leads to an 
expanded cancer-associated inflammatory program that 
when combined with non-carcinogenic low doses of the 
environmental carcinogen N-nitrosomethylbenzylamine 
(NMBA), elicited a 67% incidence of ESCC [17]. Among 
the up-regulated genes were genes known as hallmarks 
of cancer-related inflammation (chemokines, cytokines, 
prostaglandins) implicated in the development of human 
cancers, including ESCC [18, 19]. Again, ZR reversed 
this inflammatory gene signature and prevented cancer 
formation [17, 20]. Thus, our ZD rat esophageal cancer 
model reproduces the path to human ESCC and provides 
an opportunity to understand the molecular basis of ESCC 
associated with ZD.
MicroRNAs (miRNA) are short non-coding RNAs 
that regulate gene expression by translational inhibition 
and mRNA degradation. Individual miRNAs can inhibit 
multiple target genes or entire signaling pathways, 
including cell proliferation, differentiation, and apoptosis. 
miRNA expression levels are altered in all human cancers 
studied, including ESCC [21], can act as oncogenes 
or tumor suppressors [22, 23] and have emerged as 
therapeutic targets for cancer [24]. Using the NanoString 
microRNA expression profiling platform, we showed that 
ZD promotes ESCC by inducing an oncogenic miRNA 
signature that resembles the human ESCC miRNAome 
[25] with up-regulation of oncogenic miR-31, -223, and 
-21 [26-28]. Additionally, ESCC development and the 
underlying miRNA dysregulation are dependent on the 
extent of dietary deficiency of Zn [28].
In the early 1920s, Warburg discovered that unlike 
normal tissues, tumor cells convert glucose to lactate 
even under aerobic condition, establishing that cancer 
cells exhibit altered cellular metabolism fundamental 
to carcinogenesis [29, 30]. In the ensuing years, this 
phenomenon of aerobic glycolysis or Warburg effect 
has been documented in a variety of human cancers, 
including ESCC [31], most readily by assessing glucose 
uptake using positron emission tomography (PET) with a 
radiolabeled analog of glucose (118F-fuorodeoxyglucose, 
FDG) as reporter. Altered metabolism is now considered a 
hallmark of cancer [14], and deregulated uptake of glucose 
is a common feature of cancer-associated metabolic 
changes [32]. 
Given that altered metabolism results from 
active reprogramming by altered oncogenes and 
tumor suppressors [33], these metabolite changes are 
downstream and complementary to changes in genes 
and proteins and are key players in biological networks. 
Additionally, miRNAs have emerged as key regulators of 
cellular metabolism in normal and pathological conditions 
[34]. For example, miR-122 and its host gene regulate 
cholesterol and lipid metabolism in liver [35]; miR-143 
and its target gene, HK2, regulates aerobic glycolysis in 
tumor cells [36-39]. 
We hypothesized that in addition to inducing a 
hyperplastic esophageal phenotype along with oncogenic 
alterations in mRNA and miRNA gene expression, 
dietary ZD also causes altered cellular metabolism during 
early esophageal carcinogenesis. To investigate this, 
we performed untargeted metabolomic profiling by gas 
chromatography time-of-flight mass spectrometry (GC-
TOF MS) to evaluate metabolite changes in esophageal 
mucosa obtained from ZD rats vs ZS rats [16]. GC-TOF 
MS based metabolic profiling has been used for studying 
primary metabolism (sugars, lipids, & small peptides) in 
the characterization of human cancers such as ovarian 
carcinoma [40, 41] and lung adenocarcinoma [42-44]. 
To gain insights into the molecular basis of alterations in 
biochemical pathways, we integrated metabolomics of 
ZD rat esophagus with our reported transcriptome dataset 
for this tissue from a study of identical design [16]. We 
also investigated whether a miRNA-mRNA-metabolite 
network can be established in early ZD-associated 
esophageal tumor development by searching our reported 
miRNA profile data [28]. 
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RESULTS
Esophageal mucosa samples for GC-TOF MS-
based analysis
Esophageal mucosa samples were obtained from 
Zn-modulated rats after a 6-week dietary regimen as 
described before [16]. Consistent with previous studies 
[15, 16, 20], the Zn status marker, testis Zn content (µg/g 
dry weight, mean ± SD), was significantly lower in ZD 
than control ZS rats (105 ± 18 vs 131 ± 6.8, P < 0.01, n 
= 8 rats/group). Also, the ZD esophagus was hyperplastic 
with a high rate of cell proliferation, as compared with ZS 
esophagus that is typically 2 to 3 cells thick. Seventy-two 
hours after replenishing Zn, testis zinc content in ZR rats 
was 139 ± 11 µg/g dry weight, a result comparable to ZS 
rats. At the same time, ZR esophagus reverted to a near 
normal esophageal phenotype, consistent with previous 
studies [16, 20]. 
Metabolic profile of hyperplastic ZD esophagus
Metabolomic analysis by GC-TOF MS in 
esophageal mucosa from ZD and ZS rats (n = 8 per group) 
yielded a total of 353 compounds, of these 155 were 
structurally known metabolites and 198 were unknown 
compounds. Using a cutoff point of P value < 0.05 and 
≥ 1.3-fold difference, the proliferative ZD esophagus 
exhibited a distinct metabolic signature as compared with 
its non-proliferative ZS counterpart. A total of 71 known 
metabolites were significantly altered, with 27 metabolites 
down-regulated and 44 up-regulated (Table 1). To display 
the biochemical differences between hyperplastic ZD and 
control ZS esophagus, a metabolomic network [45] was 
calculated among the structurally identified metabolites 
using the Kyoto encyclopedia of genes and genomes 
(KEGG ) databases [46] and PubChem CIDs identifiers 
[47] (Figure 1). 
Of the 27 metabolites that were significantly down-
regulated in the hyperplastic ZD esophagus, sixteen 
Figure 1: Metabolomic network of biochemical differences between hyperplastic Zn-deficient and Zn-sufficient 
esophagus. Each node represents an identified metabolite. Metabolites are connected based on biochemical relationships (red, KEGG 
RPAIRS) or structural similarity (light blue, Tanimoto coefficient ≥ 0.7). Metabolite size reflects fold-change (ZD vs ZS); node color 
represents relative change (Blue, decrease, P < 0.05; Red, increase, P < 0.05; yellow, insignificant change) metabolite size reflects absolute 
fold change (Table 1). Labels are shown for the metabolites that pass the significance cutoff (P < 0.05) 
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Table 1: Metabolomic signature in precancerous Zn-deficient rat esophagus
Metabolite name Fold change (ZD vs ZS) P-value Biological process
27 down-regulated
glucose -153 0.0002 Glycolysis/gluconeogenesis
maltose -20 0.0002 Starch & sucrose metabolism
maltotriose -9.0 0.0002 ATP-binding cassette transporters
glucose-6-phosphate -8.8 0.0011 Glycolysis/pentose phosphate pathway
mannose -7.5 0.0011 Fructose & mannose metabolism
3,6-anhydro-D-galactose -6.7 0.0100 ---
ascorbic acid -6.1 0.0009 Glutathione metabolism
1-monoolein -5.9 0.0002 ---
citric acid -5.3 0.0003 Citrate cycle (TCA Cycle)
pentadecanoic acid -5.1 0.0002 ---
hexitol -3.6 0.0002 Fructose & mannose metabolism
beta-glutamic acid -3.4 0.0022 ---
fructose -3.4 0.0002 Starch & sucrose metabolism
phosphoenolpyruvate -3.3 0.0017 Glycolysis/gluconeogenesis
myo-inositol -2.9 0.0001 Galactose Metabolism
sulfuric acid -2.9 0.0012 Purine metabolism
isoheptadecanoic acid NIST -2.9 0.0150 ---
beta-sitosterol -2.8 0.0001 Steroid biosynthesis
threonic acid -2.4 0.0018 Ascorbate & aldarate metabolism
inosine -2.3 0.0370 Purine metabolism
1,5-anhydroglucitol -2.2 0.0002 ---
sorbitol -2.1 0.0019 Fructose & mannose metabolism
hexuronic acid -2.0 0.0003 ---
raffinose -1.9 0.0027 Galactose metabolism
aspartic acid -1.8 0.0415 Amino acid metabolism
taurine -1.7 0.0019 Primary bile acid metabolism
glycerol -1.4 0.0085 Galactose/glycerolipid metabolism
44 up-regulated
putrescine 14 0.0100 Glutathione/amino acid metabolism
hexadecylglycerol NIST 10 0.0002 ---
inosine 5'-monophosphate 6.4 0.0063 Purine metabolism
indole-3-lactate 5.5 0.0140 Tryptophan degradation
cytidine-5-monophosphate 
NIST 4.7 0.0013 Pyrimidine metabolism
zymosterol 3.7 0.0000 ---
alpha-ketoglutarate 3.5 0.0380 ---
cytosine 3.3 0.0002 Pyrimidine metabolism
adenosine-5-monophosphate 3.0 0.0011 Purine metabolism
pseudo uridine 3.0 0.0100 Pyrimidine metabolism
cytidine 2.6 0.0003 Pyrimidine metabolism
cysteine 2.4 0.0000 Amino acid metabolism
octadecylglycerol 2.4 0.0030 ---
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(59%) were carbohydrates, including glucose, glucose-6-
phosphate, maltose, maltotriose, mannose, 3,6-anhydro-
D-galactose, and fructose. The remaining 41% were 
lipids (three), amino acids (three), nucleotide (one), sterol 
(one), organic acid (one), and others (two) (Figure 1 
and Table 1). Most strikingly, glucose was decreased by 
153-fold (P < 0.001). Glucose depletion was positively 
correlated with a 1.7-fold increase in lactic acid (P < 
0.001). This result indicates that the proliferating ZD-
esophageal cells vigorously consume glucose (resulting in 
glucose depletion), and produce lactic acid under aerobic 
conditions. 
Because of the need to replicate all of its cellular 
contents, proliferating cells have a high biosynthetic 
demand for amino acids, lipids, and nucleotides. Thus, in 
cancer cells aerobic glycolysis fulfills the requirement to 
support cell proliferation rather than to generate energy 
in the form of adenosine 5’-triphosphate (ATP) [48]. The 
highly proliferative ZD esophagus showed a metabolic 
profile consistent with uncontrolled proliferation. Of 
the 44 up-regulated metabolites (Table 1 and Figure 
1), many were involved in amino acid metabolism/
protein biosynthesis (putrescine, cysteine, beta-alanine, 
ethanolamine, proline, glutamine, phenylalanine, 
nicotinamide etc.), purine & pyrimidine metabolism 
(inosine 5’-monophosphate, cytidine-5-monophosphate, 
adenosine-5-monophosphate, cytidine, uric acid, 
thymidine, phosphate), unsaturated fatty acids biosynthesis 
uric acid 2.3 0.0100 Purine metabolism
succinic acid 2.2 0.0070 Citrate cycle (TCA cycle)
thymidine 2.1 0.0047 Pyrimidine metabolism
maleimide 2.1 0.0067 ---
2-ketoisocaproic acid 2.1 0.0149 Amino acid metabolism
palmitoleic acid 2.1 0.0030 Fatty acid biosynthesis
4-hydroxybutyric acid 2.1 0.0000 Butanoate metabolism
pyrophosphate 2.0 0.0043 Oxidative phosphorylation
behenic acid 2.0 0.0002 Biosynthesis of unsaturated fatty acids
aminomalonate 1.8 0.0100 ---
beta-alanine 1.8 0.0402 Pyrimidine metabolism
UDP-N-acetylglucosamine 1.8 0.0047 Amino sugar & nucleotide sugar metabolism
arachidic acid 1.7 0.0001 Biosynthesis of unsaturated fatty acids
lactic acid 1.7 0.0000 Glycolysis, pyruvate metabolism
alanine-alanine 1.7 0.0011 D-alanine metabolism
ethanolamine 1.7 0.0001 ---
xylitol 1.6 0.0380 Riboflavin metabolism
lignoceric acid 1.6 0.0044 Biosynthesis of unsaturated fatty acids
phosphate 1.6 0.0037 Oxidative phosphorylation
arachidonic acid 1.6 0.0150 Biosynthesis of unsaturated fatty acids
proline 1.5 0.0124 Amino acid metabolism
phosphoethanolamine 1.5 0.0438 Glyerophospholipid metabolism
uracil 1.5 0.0395 Pyrimidine metabolism
glutamine 1.4 0.0148 Amino acid metabolism C/N balance
phenylalanine 1.4 0.0132 Amino acid metabolism
serine 1.4 0.0000 Amino acid metabolism
alanine 1.3 0.030 Amino acid metabolism
glutamic acid 1.3 0.001 Amino acid metabolism
nicotinamide 1.3 0.021 Energy metabolism
threonine 1.3 0.009 Amino acid metabolism
glycine 1.3 0.001 Amino acid metabolism
A group of 71 significantly altered metabolites were identified in ZD vs ZS esophagus using a cutoff point of P-value ≤5% and 
fold-change ≥1.3 (n = 8 rats/cohort).  ZD = Zn-deficient; ZS = Zn-sufficient.
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(hexadecylglycerol, octadecylglycerol, arachidonic 
acid, palmitoleic acid, arachidic acid), glycolysis (lactic 
acid), and energy metabolism (nicotinamide). Of these, 
the top up-regulated metabolite was the amino-acid 
derived putrescine (up 14-fold, P < 0.01). High levels 
of polyamines, including putrescine, are associated 
with human cancers and cell proliferation through DNA 
packaging [49, 50]. In summary, untargeted metabolomic 
profiling by GC-TOF MS revealed that the proliferative 
ZD esophageal mucosa exhibits extensive remodeling of 
metabolism, including a high rate of aerobic glycolysis 
accompanied by up-regulation of many metabolites that 
serve as building blocks for biomass synthesis. 
Reversal of cancer-associated metabolic profile by 
ZR
To investigate the metabolic response following 
Zn replenishment, we performed metabolomic analysis 
Table 2:  Metabolomic profiling of esophageal mucosa from Zn-replenished rats at 72 hours after Zn-replenishment 
as compared to Zn-sufficient counterpart
Metabolite name Fold change (ZR vs ZS) P-value Biological process
13 down-regulated
glucose -20 0.0006 Glycolysis/gluconeogenesis
pentadecanoic acid -5.8 0.0002 ---
3,6-anhydro-D-galactose -3.7 0.0100 ATP-binding cassette transporters
maltose -3.1 0.0104 Starch & sucrose metabolism
sorbitol -3.0 0.0002 Fructose & mannose metabolism
linoleic acid -2.2 0.0171 Biosynthesis of prostaglandin
beta-glutamic acid -1.9 0.0371 ---
isoheptadecanoic acid NIST -1.9 0.0210 ---
fumaric acid -1.7 0.0100 Citrate cycle (TCA cycle)
hexuronic acid -1.6 0.0135 ---
1,5-anhydroglucitol -1.5 0.0047 ---
beta-sitosterol -1.5 0.0361 Steroid biosynthesis
N-acetylmannosamine -1.4 0.0348 Amino/nucleotide sugar metabolism
17 up-regulated
indole-3-lactate 2.8 0.0031 Tryptophan degradation
ornithine 2.2 0.0463 Arginine biosynthesis
tyrosine 2.0 0.0003 Amino acid metabolism
proline 1.7 0.0010 Amino acid metabolism
aminomalonate 1.7 0.0100 ---
citrulline 1.7 0.0011 Arginine biosynthesis
alanine-alanine 1.7 0.0011 D-alanine metabolism
leucine 1.7 0.0004 Amino acid metabolism
oxoproline 1.6 0.0002 ---
phenylalanine 1.6 0.0005 Amino acid metabolism
isoleucine 1.6 0.0002 Amino acid metabolism
valine 1.6 0.0002 Amino acid metabolism
methionine sulfoxide 1.5 0.0054 ---
trans-4-hydroxyproline 1.5 0.0108 Amino acid metabolism
glutamine 1.5 0.0047 Amino acid metabolism C/N balance
glycine 1.4 0.0000 Amino acid metabolism
threonine 1.4 0.0023 Amino acid metabolism
A group of 30 significantly altered metabolites were identified in ZR vs ZS esophagus using a cutoff point of P-value ≤5% 
and fold-change ≥1.3 (n = 8 rats/cohort).  ZR = Zn-replenished; ZS = Zn-sufficient
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by GC-TOF MS in restored esophageal mucosa from 
ZR rats at 72 hours after replenishing Zn (n = 8 rats). As 
shown Table 2, the number of significantly deregulated 
metabolites in ZR vs ZS esophagus was 30 (13 down-
regulated & 17 up-regulated), which is ~42% of that in 
ZD vs ZS esophagus (Table 1). In particular, glucose 
deregulation was improved from a down-regulation of 
153-fold in ZD esophagus to 20-fold in ZR counterpart 
(P < 0.001, Table 2), as compared to ZS esophagus. 
Putrescine, the top-up-regulated metabolite in ZD 
esophagus was returned to ZS status. These metabolomic 
results mirror those of transcriptomic data, in which, 
shortly after ZR the altered gene expression rapidly 
reverted to near control ZS levels, accompanied by 
reduced cell proliferation, increased apoptosis, and a 
reversal of the hyperplastic esophageal phenotype [16, 17, 
20].
Integration of metabolomics, transcriptomics, and 
miRNA profiling dataset
To identify a key deregulated biochemical and 
molecular signaling network in ZD-induced esophageal 
preneoplasia, we integrated metabolomics with 
transcriptomics of ZD esophagus from a study of identical 
design [16]. Previous microarray analysis by Affymetrix 
rat genome 230 2.0 GeneChip identified a total of 2305 
significantly deregulated genes in the hyperplastic ZD vs 
ZS esophagus (fold change ≥ 2) from rats after a 6-week 
dietary regimen [16]. A gene-metabolite integration 
network (Supplementary Figure 1) was calculated by 
queries in ZD vs ZS esophagus from the 2,305 deregulated 
genes [16] and 71 significantly deregulated metabolites 
(Table 1) and mapping with log2 fold-change using the 
GRINN database within the metabox toolbox [51]. Several 
metabolic pathways showed significant alterations at both 
the transcriptional and metabolic levels (Supplementary 
Figure 1). As examples, connections that occur between 
specific gene and metabolite were observed between Hk2 
up-regulation & glucose down-regulation; cytochrome 
P450 genes (Cyp4b1, Cyp4f6, Cyp2a1) down-regulation 
& arachidonic acid up-regulation; Atp2a2, Atp1a2 
down-regulation/Atp7a, Dusp1, Pfkfb3 up-regulation & 
phosphate (O4P-3) up-regulation; Gfpt2 down-regulation 
& L-glutamine/L-glutamic acid up-regulation. 
We focused our study on HK2-glucose link because 
of its critical role in cancer metabolism [32]. Strikingly, 
HK2 that was up-regulated 3.9-fold in hyperplastic ZD vs 
Figure 2: Gene-metabolite integration network in Zn-deficient versus Zn-sufficient esophagus reveals a direct 
connection between Hk2 up-regulation and decreased level of glucose metabolite. Biological relationship - blue, enzymatic 
transformation; green, encoding gene. Node shape represents metabolite, protein, or gene. Node color represents fold change (ZD vs ZS) 
and P < 0.05.
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Figure 3: Analysis of cell proliferation, miR-143 and HK2 expression in Zn-deficient preneoplastic and neoplastic rat 
esophageal tissues. A. qPCR analysis of miR-143 (U87 as normalizer, n = 8 rats/group; results are shown as means, error bars represent 
standard deviation). B. qPCR analysis of mRNA expression of HK2 (Psmb6 as normalizer, n = 8 rats/group; results are shown as means, 
error bars represent standard deviation). Analysis of miR-143 and HK2 expression by in situ hybridization (ISH) and immunohistochemistry 
(IHC) in formalin fixed paraffin embedded esophageal samples in - C. ZD versus ZS esophagus after a 6-week dietary regimen (n = 
8 rats/group) D. Archived samples of ESCC-bearing ZD esophagus versus tumor-free control ZS esophagus [28] (n = 10 rats/group). 
Representative hematoxylin and eosin [H&E]-stained and PCNA-stained sections are shown. miR-143 ISH signal (blue, 4-nitro-blue 
tetrazolium and 5-brom-4-chloro-3′-indolylphosphate; counterstain, nuclear fast red). HK2 expression (brown, 3,3′-diaminobenzidine 
tetrahydrochloride, counterstain, Harris modified hematoxylin). Scale bars: 50 μm (x200 magnification), 100 μm (x100 magnification, and 
25 μm (x400 magnification, inset). 
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ZS esophagus by microarray expression analysis [16] was 
directly connected to down-regulated glucose metabolites, 
namely, alpha-D-glucose and beta-D-glucose (Figure 2). 
The HK2 enzyme catalyzes the first committed step in 
glucose metabolism where glucose is phosphorylated to 
yield glucose-6-phosphate. In mammals there are four 
hexokinase isoforms, HK1, HK2, HK3, and HK4 (also 
known as glucokinase). Only HK2 is expressed at high 
levels in cancer cells [52, 53], thus accounting for the high 
glycolytic rate in cancer cells [54]. Thus, by combining 
metabolomics and transcriptomics, we have identified an 
aerobic glycolysis network that involves HK2 and glucose 
signaling associated with uncontrolled cell proliferation in 
early esophageal cancer development induced by dietary 
ZD.
Using the NanoString miRNA expression profiling 
platform, we previously reported that prolonged ZD 
(22 weeks) induced extensive alterations in miRNA 
expression in the hyperplastic ZD esophagus, and many of 
the dysregulated miRNAs are similarly altered in human 
ESCC [28]. In a search for known miRNAs that regulate 
HK2, we examined this published miRNA profiling data 
for ZD esophagus [28]. Significantly, miR-143, a tumor 
suppressor in human cancers, including ESCC [55, 56], 
and a known negative regulator of HK2 [36], was down-
regulated 1.8-fold (P = 0.0136) in the highly proliferative 
ZD esophagus as compared to its non-proliferative 
counterpart vs ZS [28]. Based on this observation, we 
went on to perform Taqman miRNA assays using qPCR 
and showed that the tumor suppressor miR-143 was down-
regulated 2.5-fold in hyperplastic ZD vs ZS esophagus 
from rats after a brief 6-week dietary regimen (P < 0.05, n 
= 8 rats/group), and down-regulated 10-fold (P < 0.001, n 
= 8 rats/group) in archived samples of ESCC-bearing ZD 
esophagus vs non-ESCC-bearing ZS counterpart from an 
esophageal tumor study in Zn-modulated rats [28]. In an 
inverse manner, qPCR analysis showed that Hk2 mRNA 
levels were significantly up-regulated in these same ZD 
tissues (up 5.8-fold in hyperplastic ZD vs ZS esophagus 
& up 5.4-fold in archived samples [28] of ESCC-bearing 
ZD esophagus vs non-ESCC-bearing ZS esophagus (P < 
0.01 to P < 0.001, n = 8 rats/group) (Figure 3B). Thus, 
integration of metabolomics with transcriptomics [16] 
& microRNA profiling data [28] in the hyperplastic ZD 
esophagus revealed that deregulated glucose uptake 
is accompanied by miR-143 down-regulation and up-
regulation of the hexokinase gene Hk2. This result is 
consistent with reports that miR-143 is an essential 
regulator of cancer glycolysis by targeting HK2 in cancer 
cells, including lung cancer, head and neck squamous cell 
carcinoma, renal cell carcinoma, and colon cancer cells 
[36-39].
Divergent inverse correlation of miR-143 & 
HK2 expression in nonproliferative esophagus vs 
proliferative ZD esophageal neoplasia and human 
ESCC
To understand the distribution and localization 
of miR-143 in esophageal neoplasia in relation to 
localization of its target HK2 protein and the level of cell 
proliferation, we performed in situ hybridization (ISH) 
and immunohistochemical staining (IHC) on near serial 
sections of rat esophageal tissues (n = 10 rats/group), as 
well as in the archived human ESCC tissues for which 
we previously reported overexpression of miR-31, -21, 
-223 [27, 28]. Cellular origin of miR-143 was defined by 
ISH using high affinity double Dig-labeled LNA probes 
(Exiqon, Vedbaek, Denmark). Localization of HK2 
protein and the cell proliferation marker PCNA [56] were 
evaluated by IHC. 
Both nonproliferative ZS esophagus (after a 
6-week dietary regimen) and non-ESCC-bearing ZS rat 
esophagus (from an esophageal tumor study) showed 
few PCNA-positive nuclei, mostly restricted to basal 
cell layer (Figure 3C and 3D). Concurrently, these ZS 
tissues showed abundant and intense miR-143 ISH signal 
in basal and suprabasal cell layers along with weak HK2 
protein expression. This finding indicates that robust 
expression of this miRNA suppresses HK2 expression, 
effects that support normal cell growth. By contrast, the 
highly proliferative preneoplastic ZD esophagus, as well 
as ESCC-bearing ZD esophagus displayed a high rate of 
cell proliferation with abundant PCNA-positive nuclei in 
many cell layers. At the same time, both preneoplastic 
and cancerous phenotypes exhibited weak/diffuse 
miR-143 ISH signals but moderate/strong cytoplasmic 
HK2 expression (Figure 3C and 3D), indicating down-
regulation of the tumor suppressor, miR-143, leads to 
overexpression of HK2 and enhanced cell proliferation/
ESCC development. Together, these data revealed for the 
first time the opposing inverse-correlation between miR-
143 & HK2 expression in normal esophagus with limited 
cell growth (ZS esophagus) and precancerous/cancerous 
ZD esophageal cells with unbridled cell proliferation. 
Using the same human ESCC tissues in which we 
previously documented overexpression of miR-31, miR-
21, miR-223 by ISH [28], Figure 4 shows these human 
ESCC tissues were also highly proliferative with numerous 
PCNA-positive nuclei (n = 12 cases). While miR-143 
ISH signals were absent in human ESCC tissues, strong 
cytoplasmic HK2 protein expression was present (Figure 
4). This result is typical of all 12 patients studied and is 
consistent with that in the ZD preneoplastic/cancerous 
esophageal tissues.
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Figure 4: Analysis of cell proliferation, miR-143 and HK2 expression in human esophageal squamous cell carcinoma 
(ESCC) tissue by in situ hybridization and immunohistochemistry. Representative hematoxylin and eosin [H&E]-stained 
and PCNA-stained ESCC tissues (2 cases are shown). miR-143 ISH signal (blue, 4-nitro-blue tetrazolium and 5-brom-4-chloro-3′-
indolylphosphate; counterstain, nuclear fast red) was absent in ESCC tumor area. HK2 expression (brown, 3,3′-diaminobenzidine 
tetrahydrochloride) was moderate to strong in near serial formalin-fixed, paraffin-embedded sections of ESCC tumor tissue (Case 1 & 2). 
Scale bars: 50 μm (x200 magnification), and 25 μm (x400 magnification, inset) (n  =  12 cases).
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DISCUSSION
In the current study, untargeted metabolomic 
profiling by GC-TOF MS showed that the highly 
proliferative ZD rat esophagus has a distinct cancer-
associated metabolomic signature as compared with 
nonproliferative ZS counterpart (Table 1). Glucose down-
regulation (153-fold, P < 0.001) was accompanied by 
up-regulation of lactic acid (1.7-fold, P < 0.001), a result 
indicating a high rate of aerobic glycolysis (the Warburg 
effect), a common feature of cancer cell metabolism. 
At the same time, almost all of the 44 metabolites that 
were up-regulated were intermediate precursors needed 
for amino acid metabolism/protein biosynthesis, purine 
& pyrimidine metabolism, or lipid biosynthesis. These 
finding emphasize the requirement of cell proliferation to 
provide building blocks to support de novo biosynthesis 
needed to produce new cells [48]. Importantly, the 
dysregulated metabolites, including glucose, were highly 
Zn-responsive. Zn-replenishment rapidly increased 
glucose content and restored many deregulated metabolites 
to control levels (Table 2), accompanied by reversal of the 
hyperplastic phenotype. Taken together, the metabolomic 
data establish for the first time that the nutrient, Zn, 
regulates cancer metabolism in esophageal neoplasia 
development and reversal. This result is consistent with 
the ZR effect on the reversal of altered gene expression in 
esophageal neoplasia [16, 17].
To date, there are only a few metabolomic profiling 
studies in human ESCC; most of which were performed on 
biofluids from ESCC patients (plasma, serum, and urine). 
Only one study was conducted on human ESCC tissues 
vs normal mucosae using nuclear magnetic resonance, 
where glucose down-regulation and up-regulation of 
short-chain fatty acid were correlated with the stage of 
ESCC [57], consistent with our metabolomic profile of the 
preneoplastic rat esophagus induced by ZD. 
Human cancers have been extensively profiled by 
transcriptomic- and miRNA-based studies and increasingly 
by metabolic profiling, owing to recent advances in 
metabolomic platforms. Efforts to integrate these multi-
level events to form gene-metabolite networks have led to 
a better understanding of the molecular basis of cancer. In 
the current study, to decipher the mechanism underlying 
aberrant glucose metabolism induced by dietary ZD in the 
earliest stage of esophageal carcinogenesis, we performed 
an integrated analysis of metabolomics with our published 
transcriptomics for preneoplastic ZD rat esophagus [16]. 
This analysis uncovers a direct link between glucose 
down-regulation and up-regulation of the glycolytic 
enzyme HK2 (Figure 2). HK2 catalyzes the first step of 
glycolysis and is overexpressed in many human cancers, 
including ESCC. Several other enzymes in glycolysis are 
also increased in cancer cells, but unlike HK2 they are 
also expressed in normal cells [58]. Genetic deletion of 
HK2 has been reported to reduce the overall tumor burden 
in lungs in a genetic mouse lung cancer model, indicating 
a role of HK2 in tumor initiation [58]. In patients with 
ESCC, a positive correlation is well established between 
a high 18F-FDG uptake (a marker for tissue uptake of 
glucose) and HK2 activity in resected specimen [59, 60]. 
Thus, our finding of a HK2-glucose link in hyperplastic 
ZD esophagus highlights the critical role of HK2 in 
deregulated glucose metabolism in early esophageal tumor 
development by ZD. 
It is now well recognized that miRNAs play a 
critical role in regulating cellular metabolism in health 
and disease, including cancer, thereby generating a 
bidirectional functional link in the crosstalk between 
miRNA and metabolism [34, 61]. The most pronounced 
metabolic alteration in cancer cells is deregulated uptake of 
glucose and associated aerobic glycolysis [14, 32]. Critical 
to cancer aerobic glycolysis is the glycolytic enzyme HK2 
that catalyzes the first committed step in glycolysis [54]. 
In this study, integrated analysis of -omics datasets with 
miRNA expression profiling revealed a miR-143-HK2-
glucose link in hyperplastic ZD esophagus. Moreover, we 
showed that miR-143 regulates cancer glycolysis in ZD-
induced esophageal neoplasia by targeting HK2 (Figure 
3), a result consistent with reports for lung cancer, renal 
cell carcinoma, head and neck squamous cell carcinoma, 
breast cancer, and prostate cancer [36-38, 62, 63].
A limitation of this current study is the fact that 
only the HK2-glucose gene-metabolite network is 
studied in detail. Future studies are needed to investigate 
other gene-metabolite connections in our integrated 
analysis of metabolomics and transcriptomics (Figure 2, 
Supplementary Figure 1). In addition, future studies are 
needed to unravel the mechanism(s) whereby dietary ZD 
regulates the expression of miR-143.
In summary, our metabolomic profiling reveals that 
increased consumption of glucose is the most prominent 
metabolic alteration in the highly proliferative ZD 
esophagus. The finding that ZR rapidly corrects aberrant 
metabolite levels, including that of glucose, indicates that 
Zn regulates glucose metabolism in esophageal cancer 
initiation and reversal. Integration of metabolomics with 
our published transcriptomics and microRNA profiling 
data revealed a miR-143-HK2-glucose pathway that 
underlies esophageal neoplasia by ZD. The finding shows 
that to support cell proliferation, ZD reprograms glucose 
metabolism by modulating the expression of miR-143, 
which targets HK2. Altogether, our data advance the 
understanding of the mechanistic role of Zn in ESCC 
development and prevention.
MATERIALS AND METHODS
Rat studies
The Animal protocol was approved by the Thomas 
Jefferson University Animal Care and Use Committee. 
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Male weanling Sprague-Dawley rats (50 ± 5 g) were 
obtained from Taconic Laboratory (Germantown, NY). 
Custom-formulated ZD and ZS diets (Harlan Teklad, 
Madison, WI) were identical except for the amount of 
zinc, which was 3-4 ppm for ZD and ~60 ppm for ZS 
diet. Weanling male rats (n = 48) were fed a ZD (n = 32) 
or ZS (n = 16) diet for 6 weeks to establish esophageal 
proliferation in ZD rats [16, 20, 27]. ZD rats were fed 
ad libitum and ZS rats were pair-fed to ZD animals to 
match the decreased food consumption of ZD rats [16, 
20, 27]. After 6 weeks ZD rats evidenced increased cell 
proliferation in the esophagus, as assessed by increased 
expression of proliferating cell nuclear antigen PCNA 
[15]. Zinc gluconate (1.0 mg elemental zinc) in saline was 
then administered intragastrically to 16 ZD rats, which 
were immediately switched to the ZS diet to form the 
ZR group. At 72 hours after replenishment, all animals 
(ZD, ZR, and ZS, n = 16 rats/group) were killed. Whole 
esophagus was excised and collected onto ice to minimize 
further metabolism. Esophageal epithelia (n = 10 rats/
group) were prepared by using a blade to remove the 
submucosal and muscularis layers, snap-frozen in liquid 
nitrogen, and stored at -80oC [16, 64]. The remaining 
esophageal samples were fixed in 10% buffered formalin 
and paraffin embedded.
GC TOF MS data acquisition and processing
For metabolomic profiling, frozen esophageal 
samples from ZD, ZS, and ZR rats (n = 8 rats per group; 
20 mg per esophagus) were shipped on dry ice to the 
NIH West Coast Metabolomics Center, University of 
California, Davis. Esophageal tissue was extracted and 
derivatized as described [40, 42]. For primary metabolites 
analysis by GC-TOF MS, the cold injection/automatic 
liner exchange gas chromatography-time of flight mass 
spectrometry (CIS-ALEX GC-TOF MS, Leco Pegasus 
IV) was employed using chromatographic and mass 
spectrometric parameters as previously described [40, 
42]. From around 800 individual peaks detected per 
chromatogram, 353 genuine metabolites remained after 
extensive cleanup and filtering through the BinBase 
metabolomic database. Using the Fiehnlib libraries 
of over 1,200 mass spectra and retention indices for 
identified metabolites, 155 compounds per studies were 
be structurally identified by matching mass spectra and 
retention indices to authentic standards (MSI [65] level 
1 identifications) or annotated by very high mass spectral 
similarities to the NIST14 library and close retention time 
predictions (MSI level 2 identifications, name followed by 
the label “NIST” in the Tables 1 and 2). A quality control 
sample for extracts was prepared by mixing small biofluid 
(~5 μl) of each sample in a study set, thus providing a 
sample with the true representation of the breadth of 
metabolites present in the sample set.
Statistical analysis
For analysis involving only 2 sets of data, a student’s 
t-test or welch t-test was used depending on a F-test for 
differences in variance. For analysis involving multiple 
comparisons of all 3 groups (ZD, ZS and ZR), a Shapiro-
Wilk Normality test was performed for each group. If any 
group failed the normality test, an overall Kruskal-Wallis 
chi-squared test was performed to test if there were any 
differences among the groups. A significant Kruskal-Wallis 
result was followed by pairwise Wilcoxon rank sum test to 
identify the differences between individual groups. In the 
case where no group failed the normality test, the Levene’s 
homogeneity of variance test was performed. For datasets 
that were homoscedastic, a standard one-way ANOVA for 
overall differences was performed, followed by the Tukey 
HSD pot-hoc t-test for determination of differences among 
the groups. For heteroscedastic data, a Welch one-way 
ANOVA was performed, followed by the Games-Howell 
post hoc t-test for determination of differences among the 
groups. Statistical tests were 2-sided and were considered 
significant at P≤0.05. Statistical analysis was performed 
using R (http://www.R-project.org).
Metabolome network visualization
Network analysis was used to investigate statistical 
and multivariate modeling results within a biochemical 
context. A biochemical and chemical similarity network 
[45] was calculated for all measured metabolites with 
KEGG [46] and PubChem CIDs [47]. Enzymatic 
interactions were determined based on product-precursor 
relationships defined in the KEGG RPAIR database. 
Molecules not directly participating in biochemical 
transformations, but sharing many structural properties, 
based on PubChem Substructure Fingerprints [66], were 
connected at a threshold of Tanimoto similarity coefficient 
≥ 0.7.
The table of metabolites (nodes) and network 
properties (p-values, direction of change) provided by 
MetaMapp were imported into the Cytoscape software and 
networks were generated by the organic layout algorithm 
in Cytoscape. Red and blue nodes show the increase and 
decrease in the amounts of metabolites, respectively. 
The blue lines reflect chemical similarity and red lines 
show biochemical reactions. Labels are not shown for 
metabolites that did not pass significance tests.
Integrating metabolomics with gene expression 
data
A genomics/metabolomics integration network from 
the data the metabolic profile in ZD rat esophagus was 
integrated with our published transcriptome dataset for this 
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tissue ( > 2300 dysregulated genes, identical study design 
as metabolomics data) [16]. The network contains genes, 
proteins and metabolites. It was queried from significant 
genes and metabolites (P-value < 0.05) and mapped with 
log2 fold-change.
Integrating gene expression data with miRNA 
profiling data
To find known miRNAs that regulate HK2, we 
searched our published miRNA profiling data for ZD 
esophagus [28].
Rat esophageal samples for qPCR, TaqMan 
miRNA assay, ISH & IHC assays
For analyses involving 6 wks-ZD esophagus, 
esophageal tissues from the current metabolomic profiling 
study were used. For analyses involving esophageal 
tumor endpoint, archived samples of ESCC-bearing ZD 
esophagus and tumor-free control ZS esophagus from a 
previous study [28] were employed.
RNA isolation
Esophageal epithelial samples frozen in liquid 
nitrogen were pulverized to a fine powder using a chilled 
hammer. Total RNA was extracted from the pulverized 
samples using an animal tissue RNA extraction Kit 
(#25700, Norgen Biotek, Ontario, Canada). RNA 
concentration of each sample was determined using a 
NanoDrop 1000 (Thermo Scientific). All RNA samples 
displayed a 260:280 ratio > 1.8, and a 260:230 ratio > 1.8.
qPCR
cDNA was reverse transcribed using the High-
Capacity cDNA Archive Kit (Applied Biosystems, Foster 
City, CA) according to the manufacturer’s protocol. 
qPCR was performed using pre-designed probes (Applied 
Biosystems), Psmb6 and Oaz1 as the normalizers, and the 
comparative Ct method.
TaqMan miRNA assay
Reverse transcription of miRNAs was performed 
according to the manufacturer’s instructions (Applied 
Biosystems, Foster City, CA) with a reaction volume of 
15 μl containing 350 ng of total RNA. Real-time qPCR 
was performed using StepOnePlus Real-time System 
(Applied Biosystems). Each miRNA and endogenous 
control (snoRNA and U87) was measured in triplicates. 
As an overall quality control, Ct (cycle threshold) values 
above 35 were excluded from analysis.
Human ESCC samples
Twelve cases of FFPE human ESCC samples were 
obtained from Thomas Jefferson University Hospital 
(Philadelphia, PA).
In situ hybridization
miRCURY locked nucleic acid (LNA)™ microRNA 
detection probes, namely, hsa-miR-143, rno-miR-31, and 
negative controls were purchased from Exiqon (Vedbaek, 
Denmark). The oligonucleotides are double DIG-labeled 
at the 5’- and 3’-ends. ISH was performed on 6 µm FFPE 
sections as previously described [26-28]. Following 
deparaffinization, rehydration in graded alcohol and 
proteinase K treatment, tissue sections were hybridized 
with miR-143 probe (20 nM), in hybridization buffer 
(Exiqon) at 57oC for 14 h in a hybridizer (Dako, Glostrup, 
Denmark). Following stringent washes in SSC buffers, 
the sections were blocked against unspecific binding of 
the detecting antibody, using DIG wash and blocking 
reagent. miRNA was localized by incubation with 
4-nitro-blue tetrazolium (NBT) and 5-brom-4-chloro-3′-
indolylphosphate (BCIP) (Roche, Mannheim, Germany). 
Nuclear fast red (Vector Lab., Burlingname, CA) was used 
as a counterstain. 
Immunohistochemistry (IHC)
FFPE tissues were deparaffinized, and rehydrated 
in graded alcohols. IHC was carried out as previously 
described [20, 27], using anti-hexokinase 2 antibody 
[3D3] (#NBP1-51643, mouse monoclonal, Novus 
Biologicals, Littleton, CO, USA) and PCNA antibody 
(clone PC-10, Ab-1, Thermo Scientific, Waltham, MA, 
USA), after citrate-based antigen retrieval. Protein was 
localized by incubation with 3-amino-9-ethylcarbazole 
substrate-chromogen (Dako, Carpinteria, CA, USA) or 
3,3’-diaminobenzidine tetrahydrochloride (Sigma-Aldrich, 
St Louis, MO, USA).
Microscopy
IHC and ISH analyses were performed by light 
microscopy using an Olympus BX51 microscope and 
photographs taken with a Spot RT3 camera and Spot 
software v. 4.6.
Zn content analysis
Serum Zn content is determined by atomic 
absorption spectrometry [16].
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